Depressive Symptoms, HIV Medication Adherence, and HIV Clinical Outcomes in Tanzania: A Prospective, Observational Study by Belenky, Nadya M. et al.
Depressive Symptoms, HIV Medication Adherence, and
HIV Clinical Outcomes in Tanzania: A Prospective,
Observational Study
Nadya M. Belenky1*, Stephen R. Cole1, Brian W. Pence1,2, Dafrosa Itemba3, Venance Maro4,
Kathryn Whetten2
1 Department of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America, 2 Center for
Health Policy & Inequalities Research, Duke Global Health Institute, Department of Community and Family Medicine, Duke University, Durham, North Carolina, United
States of America, 3 Tanzania Women Research Foundation, Moshi, Tanzania, 4 Kilimanjaro Christian Medical Center, Moshi, Tanzania
Abstract
Depressive symptoms have been shown to independently affect both antiretroviral therapy (ART) adherence and HIV
clinical outcomes in high-income countries. We examined the prospective relationship between depressive symptoms and
adherence, virologic failure, and suppressed immune function in people living with HIV/AIDS in Tanzania. Data from 403
study participants who were on stable ART and engaged in HIV clinical care were analyzed. We assessed crude and adjusted
associations of depressive symptoms and ART adherence, both at baseline and at 12 months, using logistic regression. We
used logistic generalized estimating equations to assess the association and 95% confidence intervals (CI) between
depressive symptoms and both virologic failure and suppressed immune function. Ten percent of participants reported
moderate or severe depressive symptoms at baseline and 31% of participants experienced virologic failure (.150 copies/
ml) over two years. Depressive symptoms were associated with greater odds of reported medication nonadherence at both
baseline (Odds Ratio [OR] per 1-unit increase = 1.18, 95% CI [1.12, 1.24]) and 12 months (OR = 1.08, 95% CI [1.03, 1.14]). By
contrast, increases in depressive symptom score were inversely related to both virologic failure (OR = 0.93, 95% CI [0.87,
1.00]) and immune system suppression (OR = 0.88, 95% CI [0.79, 0.99]), though the association between depressive
symptoms and clinical outcomes was less precise than for the association with nonadherence. Findings indicate a positive
association between depressive symptoms and nonadherence, and also an inverse relationship between depressive
symptoms and clinical outcomes, possibly due to informative loss to follow-up.
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Introduction
Clinical outcomes of HIV have dramatically improved since the
widespread adoption of modern combination antiretroviral
therapy (ART), which has enhanced quality of life and increased
survival time among people living with HIV/AIDS (PLWHA)
[1,2]. However, despite ART’s success, PLWHA who are on ART
still exhibit variability in adherence and clinical outcomes [3]. This
variability has been partially attributed to behavioral and
psychosocial factors, including depression [4–8].
The effects of the mental health disease burden in PLWHA may
be exacerbated by lack of treatment options. The World Health
Organization’s most recent estimates from the Mental Health Gap
Action Programme indicate that 75% of those in need of mental
health treatment do not have access to services [9]. Furthermore,
despite similar prevalence of mental health disorders, mental
health resources vary widely by country; in low-income countries,
the World Health Organization calculated a median number of
0.3 mental health professionals per 100,000, compared to a
median number of 70 per 100,000 in high-income countries [10].
Depressive symptoms are thought to influence treatment
initiation and maintenance of PLWHA through different path-
ways, from immunological response to health-related behaviors.
Studies have shown that depressive symptoms predict differences
in HIV disease progression, even after controlling for ART
adherence [8]. Depressive symptoms have also been linked to
general suppressed immune function [11], increased HIV-1 viral
load (VL) [12], faster progression to AIDS [4], as well as higher all-
cause and HIV-related mortality [13–16]. Depressive symptoms
also affect health-related behaviors and have been linked to illicit
drug use, alcohol consumption, and reduced ART adherence
[17,18].
The effects of depressive symptoms are also not restricted to
high-income countries. A recent systematic review on ART
adherence in sub-Saharan Africa [19] estimated the prevalence
of depressive symptoms was 31%, pooled over 23 studies and 9
countries, and that the likelihood of achieving good ART
adherence was 55% lower among PLWHA with depressive
symptoms compared to those without. However, 20 of the 23
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studies on depressive symptoms were cross-sectional, most
consisted of individuals with advanced HIV, and access to care
varied widely.
Previous studies have examined the independent associations of
depressive symptoms and HIV clinical outcomes. To date,
however, no study has considered the relationship of depressive
symptoms with ART adherence and HIV clinical outcomes at
separate time points in a sub-Saharan population in established
medical care.
Using data from the Coping with HIV/AIDS in Tanzania
(CHAT) study, we quantify the association of baseline depressive
symptoms on ART adherence at baseline and 12-months as well as
examine the relationship between baseline depressive symptoms
and both virologic failure and suppressed immune function at any
point during follow-up (i.e., 12, 24, or 36 months). We hypothesize
that participants with high depressive symptom scores are more
likely to report nonadherence than those with low depressive
symptom scores, and that participants with high depressive
symptom scores are more likely to experience virologic failure
and suppressed immune function. The results of this study will add
to the limited body of knowledge on the relationship between
depressive symptoms on both ART adherence and HIV clinical
outcomes in low- and middle-income countries.
Methods
Participants
The CHAT Study is a prospective observational study that
examines the relationship between psychosocial characteristics,
ART adherence, and HIV health outcomes. The study recruited
1,191 participants in Moshi, Tanzania, between November 2008
and October 2009. Study participants form five cohorts: patients
with established HIV infection receiving care at a tertiary referral
hospital (n = 227), patients with established HIV infection receiv-
ing care at a public hospital (n = 271), individuals recently
diagnosed with HIV (n = 263) or tested negative for HIV
(n = 181) at voluntary counseling and testing sites, and a random
community sample of adults (n = 249). Sampling, recruitment, and
selection procedures are described in more detail elsewhere [20].
All participants complete standardized in-person interviews in
Swahili every six months. In addition to measurements obtained
during the clinical exam at study initiation, participants with
established HIV infection also provide blood samples for VL
during a clinical exam every 12 months and corresponding CD4
cell counts are abstracted from medical records.
We restricted this analysis to participants with established HIV
infection (i.e., who were either receiving care at a tertiary referral
hospital or a public hospital, n = 498). We further restricted the
sample to participants who were on ART at baseline (n = 403).
Written, informed consent was obtained from all participants. The
study was approved by the Kilimanjaro Christian Medical Center
Institutional Review Board in Tanzania and the Duke University
Health System Institutional Review Board in the United States.
Measurements
Age, gender, marital status (i.e., single, married, divorced/
widowed), education (i.e., none, primary, secondary, university),
and household assets were assessed at baseline using the in-person
questionnaire. Possible household assets included access to:
running water, a flush toilet, and/or a television; each asset
contributed one point to the household asset score (range: 0–3).
Depressive symptoms were measured using the Patient Health
Questionnaire (PHQ-9), a nine-item questionnaire taken from the
Primary Care Evaluation of Mental Disorders [21,22], which has
been validated in similar populations [23,24]. For each of the nine
items, participants were asked how often they experienced the
corresponding symptom during the previous two weeks. Individual
items are scored on a 0–3 scale. Total scores for depressive
symptoms range from 0–27, where higher scores indicate greater
depressive symptom severity. In this analysis, depressive symptoms
at baseline were examined continuously.
The outcomes of this study were ART nonadherence at baseline
and 12 months, ever having experienced a virologic failure, or ever
having had suppressed immune function. ART nonadherence was
assessed using a combination of four ART adherence questions.
Answering affirmatively that a dose had been missed within the
last month or indicating either that doses were missed, forgotten
about, or skipped; not all doses were taken; or that doses were
taken more than one hour early or late. All indications of missed or
mistimed doses were assessed using a visual guide. The definition
of ART nonadherence included dose timing based on previous
findings that dose timing error was significantly related to HIV VL
[25].
Plasma for VL measurements was collected from participants in
10-ml Vacutainer tubes containing potassium ethylenediaminetet-
raacetic acid and was stored at 280uC until testing. VLs were
quantified by HIV-1 RNA extracted from 1.0-ml plasma samples
using an isothermal nucleic acid sequence-based amplification
method. This assay has a lower detection limit of 40 or
150 copies/ml depending on the lowest sample volume of the
run, and is linear to concentrations as high as 106 copies/ml. An
Abbott m2000 system was used to analyze all samples and the
study laboratory participates in an international viral quality
assurance program. Initial CD4 cell counts were obtained during
the clinical exam at study entry. During follow-up, the CD4 cell
counts that corresponded in time to the VL measurements were
abstracted from medical charts.
Statistical Analyses
For all outcomes, we adjusted for baseline measures of age,
gender, marital status, education, and asset score. We estimated
the adjusted and unadjusted association between depressive
symptoms and ART adherence (at baseline and 12 months), and
virologic failure during follow-up or suppressed immune function
at any available measurement during follow-up. Odds ratios (OR)
for ART adherence were obtained using logistic regression.
Generalized estimating equation (GEE) logistic models were used
to account for repeated measurements of viral load and CD4 cell
counts. Virologic failure was examined as a dichotomous variable,
where virologic failure was defined as a viral load of .150 copies/
ml at any point after baseline. Suppressed immune function was
also treated as a dichotomous variable, where suppressed immune
function was defined as any instance of a CD4 cell count below
200 cells/mm3 after baseline. Both GEE logistic models of
virologic failure and suppressed immune function were also
examined after adjusting for baseline values of viral load and
CD4 cell count, respectively. All statistical analyses were
performed using STATA version 12.1 for Mac (Stata Corporation,
College Station, Texas).
Results
Of the 403 participants, 69% (n = 276) of the participants were
female and the median age was 42 years (IQR: 36–48).
Approximately 37% of the study participants were married or
co-habitating, 14% had never married, 28% were widowed, and
20% were divorced. Seventy-four percent (n = 297) of participants
had received a primary education and the median asset score was
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2, corresponding to ownership of two of the three measured assets:
running water, a flush toilet, or a television.
Levels of depressive symptoms were low: only 10% (n = 40) of
participants had a score indicating moderate or severe depressive
symptoms (PHQ-9$10) and 23% (n = 94) had scores indicating of
mild, moderate, or severe depressive symptoms (PHQ-9$5). At
baseline, the median CD4 count was 305 cells/mm3 (IQR: 191–
443 cells/mm3). The majority of participants had a suppressed VL
at baseline (82%), where suppression was defined as a VL of #
150 copies/ml (Table 1).
VL measurements at baseline were available for 375 partici-
pants (93%) and a high percentage of participants had VL
measurements at 12, 24 and 36 months (84%, 86%, and 91%,
respectively). The proportion of participants experiencing virologic
failure changed over time, ranging from 10% to 19%, and 31% of
participants experienced at least one virologic failure. CD4 cell
counts were based on the study’s medical exam at the initial study
visit and abstracted from medical records during follow-up. At
baseline, 285 (71%) of 403 participants had CD4 cell count
measurements. During follow-up, the number of participants with
CD4 cell count measurements was lower, where the percentage of
participants with CD4 cell counts ranged from 42% to 56%.
Overall, 97% of participants had at least one VL measurement
and 84% had at least one CD4 cell count measurement over the
time points used in this analysis (Table 2).
Results show a positive association between depressive symp-
toms and ART nonadherence both at baseline and at 12 months.
The unadjusted estimates of the relationship between baseline
depressive symptoms and ART nonadherence at baseline and 12
months ART were OR = 1.16 (95% CI: 1.10, 1.22) and 1.08 (95%
CI: 1.03, 1.14), respectively. After adjustment for potential
confounders (age, gender, marital status, education, and household
assets), the magnitude of the relationship was virtually unchanged,
resulting in an OR of 1.18 (95% CI: 1.12–1.24) and 1.08 (95% CI:
1.03, 1.14) for ART nonadherence at baseline and 12 months,
respectively. In other words, for every 1-unit increase in PHQ-9
score, the odds of being nonadherent to ART were 1.1 times
greater than the odds of being adherent. The adjusted ORs for the
effect of continuous depressive symptoms on virologic failure and
suppressed immune function show an inverse relationship with
depressive symptoms, where a higher depressive symptom score
corresponds to lower odds of virologic failure or immunosuppres-
sion (OR = 0.93 [95% CI: 0.87–1.00] and OR = 0.88 [95% CI:
0.79, 0.99], respectively) (Table 3).
Discussion
In this population of Tanzanian adults with HIV in established
medical care, we found that a continuous measure of baseline
depressive symptoms was positively associated with ART non-
adherence, both at baseline and the 12-month follow-up visit. This
positive relationship held in both the crude and adjusted results.
Increases in baseline depressive symptoms were not associated
with increased odds of either virologic failure or suppressed
immune function during follow-up.
These findings are consistent with the proposed hypothesis that
depressive symptoms are positively associated with ART non-
adherence. Furthermore, association held in both direction and
magnitude after adjustment for potential confounders. While
results indicated a positive association between depressive symp-
toms and ART nonadherence, they also indicate an inverse
Table 1. Baseline characteristics of 403 CHAT study participants, Tanzania, 2008–2009.
Characteristicas Median (IQR) or n (%)
Sample Size 403
Age 42 (36–48)
Female gender, n (%) 276 (68.5)












Suppressed immune function, n (%) (,200 CD4 cells/mm3) 76 (18.9)
Virologic failure, n (%) 72 (17.9)
Depressive symptomsc, n (%) None or mild 358 (88.8)
Moderate or severe 40 (9.9)
Nonadherent, n (%) 94 (23.3)
aMedian (IQR) unless otherwise noted.
bHousehold asset score was determined by access to: running water, a flush toilet, and/or a television.
cDepressive symptoms are measured using the Patient Health Questionnaire (range: 0–27).
doi:10.1371/journal.pone.0095469.t001
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relationship between depressive symptoms and clinical outcomes,
possibly due to informative loss to follow-up.
Because previous studies of depressive symptoms and HIV
clinical outcomes have relied on cross-sectional study designs [19],
factors previously associated with ART adherence, VL or CD4
counts may not predict change over prospective follow-up.
Furthermore, this analysis considered individuals in established
HIV clinical care, who had been on ART for at least six months.
In an ART-stabilized population, psychosocial factors may play a
more important role in determining ART adherence patterns as
well as early virologic suppression and maintenance. To our
knowledge, this is the first study to examine the relationship
between depressive symptoms, and a combination of ART
adherence and clinical outcomes using a prospective design on a
sub-Saharan population of PLWHA in established medical care.
Prospective assessment of ART adherence, CD4 cell counts,
and VL is a primary advantage of this study, resulting in stronger
causal interpretation of results due to established temporal order
between exposure and outcome. Furthermore, the CHAT study’s
emphasis on psychosocial factors is less common in low-income
countries, despite the combination of high prevalence and reduced
access to mental health services. Although this study is conducted
using a Tanzanian cohort, high ART adherence and retention
rates increase the generalizability of findings to other populations
that have similar ART adherence patterns and access to
treatment. Another advantage of the CHAT Study is the
measurement of depressive symptoms by the PHQ-9, which has
been previously validated specifically in PLWHA in sub-Saharan
Africa [23,24]. Finally, the high retention in the cohort over the
two year study period, for both psychosocial and clinic visits,
makes bias due to drop-out less likely.
The analysis was limited by several factors. Levels of depressive
symptoms were low in the study sample, resulting in small
numbers of participants with elevated depressive symptoms and
high VL or suppressed immune function. In addition, the CHAT
Study is ongoing and not all clinical measurements were available
at the later time points. Depressive symptoms and ART adherence
measures were limited in that both are self-reported, although this
is common in studies of ART adherence and depressive symptoms
in sub-Saharan Africa [19]. Finally, while the PHQ-9 is an
effective screening tool for depressive symptoms, it does not
represent a clinical diagnosis.
This study adds to the literature on the influence of psychosocial
factors on ART adherence and HIV clinical outcomes. Previous
studies on psychosocial factors and ART adherence have
suggested that strategies for intervention directed at depressive
symptoms would have positive effects on ART adherence. This
study strengthens those results for a sub-Saharan population
receiving stable medical care. Furthermore, this study demon-
strates that, despite the positive association between baseline
depressive symptoms and ART nonadherence at baseline and 12
months, findings show an inverse relationship between depressive
symptoms at baseline and odds of both virologic failure and
suppressed immune function during follow-up. The confidence
intervals for the clinical measures were larger than the confidence
intervals for nonadherence and it is possible that the inverse
association is due to incomplete clinical data and subject to change
as more clinical data are incorporated. Longer periods of ART
nonadherence associated with depressive symptoms may also be
necessary before changes in VL or CD4 are measurable.
This analysis demonstrates an under-utilized avenue for
identifying ART nonadherence in early treatment stages and
maximizing the impact of HIV treatment. It also emphasizes the
far-reaching impact that increased capacity for mental health
screening and services can have. The association between
depressive symptoms and nonadherence in the early stages of
treatment indicates the advantage of screening for depressive
symptoms at treatment initiation. Additional research should
explore the effects of combining mental health screening and
treatment with conventional HIV care on retention in clinical
care, as well as the effects of mental health services in the later
stages of HIV disease progression. The results of this study
demonstrate the advantage of combining conventional HIV care
with mental health screening for improving medication adherence
and that, even in low- and middle-income settings, identification
Table 2. Virologic failure and immune suppression over study visits.
Outcome Measure Baseline 12 months 24 months 36 months Overall
Virologic Failure, x/na (%) 72/375 (19.2) 35/340 (10.3) 39/348 (11.2) 53/366 (14.5) 120/392 (30.6)
CD4 ,200, x/nb (%) 76/285 (26.7) 34/212 (16.0) 22/227 (9.7) 13/170 (7.7) 98/381 (25.7)
aNumber of virologic failures is indicated by x, number of available VL measurements are indicated by n.
bNumber of CD4 counts defining suppressed immune function indicated by x, number of available CD4 counts indicated by n.
doi:10.1371/journal.pone.0095469.t002
Table 3. Effect of depressive symptoms on nonadherence and clinical outcomes.
Outcome Measure Crude OR (95% CI) Adjusted ORa (95% CI)
ART Nonadherenceb (Baseline) 1.16 (1.10, 1.22) 1.18 (1.12, 1.24)
ART Nonadherenceb (12 months) 1.08 (1.03, 1.14) 1.08 (1.03, 1.14)
Virologic Failurec (VL.150 copies/ml) 0.95 (0.89, 1.01) 0.93 (0.87, 1.00)
Suppressed Immune Functionc (CD4,200 cells/mm3) 0.95 (0.86, 1.07) 0.88 (0.79, 0.99)
aAdjusted for baseline measurement of age, gender, marital status, education, and household assets.
bAny self-reported deviation from perfect ART adherence was used as indicator for nonadherence.
cFailure/suppression at any point after baseline measurement, adjusted for baseline measure of failure/suppression.
doi:10.1371/journal.pone.0095469.t003
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and treatment of depressive symptoms should be a priority for
PLWHA.
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